IOVA vs ZBH
Iovance Biotherapeutics, Inc. vs Zimmer Biomet — AI-powered side-by-side comparison
IOVA
Iovance Biotherapeutics, Inc.
67
Buy
VS
| Metric | IOVA | ZBH |
|---|
| AI Score |
67
|
69
|
| Price |
$6.49
|
$97.22
|
| P/E Ratio |
-9.27×
|
23.54×
|
| ROE |
-56.0%
|
5.6%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
116.3%
|
69.9%
|
| Debt / Equity |
0.06×
|
0.59×
|
| Dividend Yield |
0.0%
|
1.0%
|
| RSI (14) |
79.2
|
63.1
|
| Beta |
0.701
|
0.462
|
| Expected Upside |
—
|
+3.7%
|
AI Committee View
Current Innellis committee reasoning for IOVA versus ZBH.
ZBH leads by 2 points.
ZBH scores 69/100 (Buy) versus IOVA at 67/100 (Buy).
IOVA Committee View
67% agreement
6 analysts
The primary driver is revenue growing 34.5% yoy -- genuine top-line momentum. The main limiting factor is roe of only -40.5% -- cheap may mean cheap for a reason. The committee is constructive but not yet at full conviction.
Bull Case
- Revenue growing 34.5% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- ROE of only -40.5% -- cheap may mean cheap for a reason — Value
- RSI at 79 is in overbought territory — Technical
- Weekly RSI at 75 -- overbought on the larger timeframe too — Technical
ZBH Committee View
80% agreement
5 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend. The committee is constructive but not yet at full conviction.
Bull Case
- Price-to-book of 1.4x is a discount to asset value — Value
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
- Daily trend (uptrend) conflicts with the weekly trend (downtrend) -- fighting the larger trend — Technical